Hyperthyroidism Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017
Hyperthyroidism is common form of thyroid disorders, results from overactive thyroid functioning and is mostly observed in women, old population and patients with other thyroid issues. Extra secretion of thyroid hormones leads to speed up of metabolism in the body. Accordingly, patients witness symptoms of anxiety, rapid heartbeat, shivering, excessive sweat excretion, weight loss and insomnia.
Auto-immune disorder including Graves’ disease is the common cause of the condition. The disease leads the body to produce anti-body termed thyroid-stimulating immunoglobulin (TSI). The TSI results in thyroid to secrete additional thyroid hormones. In addition, lumps on thyroid gland and arrhythmia medications are also observed to cause hyperthyroidism.
Treatment options vary from patient to patient based on the condition including medication to reduce T3 and T4 hormone secretion, radioiodine and surgery.
Hyperthyroidism clinical trials report from VPA Research provides comprehensive analysis and trends in global Hyperthyroidism disease clinical trials. The research work analyzes the evolution of Hyperthyroidism clinical trial trends across countries and regions.
The report focuses on drugs and therapies being evaluated for Hyperthyroidism treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Hyperthyroidism clinical trials.
Major drugs under development in Hyperthyroidism are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.
Scope of the Report-
Auto-immune disorder including Graves’ disease is the common cause of the condition. The disease leads the body to produce anti-body termed thyroid-stimulating immunoglobulin (TSI). The TSI results in thyroid to secrete additional thyroid hormones. In addition, lumps on thyroid gland and arrhythmia medications are also observed to cause hyperthyroidism.
Treatment options vary from patient to patient based on the condition including medication to reduce T3 and T4 hormone secretion, radioiodine and surgery.
Hyperthyroidism clinical trials report from VPA Research provides comprehensive analysis and trends in global Hyperthyroidism disease clinical trials. The research work analyzes the evolution of Hyperthyroidism clinical trial trends across countries and regions.
The report focuses on drugs and therapies being evaluated for Hyperthyroidism treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Hyperthyroidism clinical trials.
Major drugs under development in Hyperthyroidism are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.
Scope of the Report-
- Number of Hyperthyroidism clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Hyperthyroidism
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
- Leading sponsors of Hyperthyroidism clinical trials worldwide are listed
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010- 2017
2.2.3 Prominent Companies in Global Hyperthyroidism Trials, 2010- 2017
3 HYPERTHYROIDISM DRUGS IN ONGOING AND COMPLETED TRIALS
3.1 Prominent Drugs in Development and Approved Stages for Hyperthyroidism
3.2 Hyperthyroidism Product Snapshots
3.2.1 Hyperthyroidism Drug Profiles
4 GLOBAL HYPERTHYROIDISM CLINICAL TRIAL RESEARCH TRENDS
4.1 Clinical Trials by Top 10 Countries, 2010- 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010- 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010- 2017
4.4 Subjects Recruited by Region, 2010- 2017
4.5 Clinical Trials by Year, 2010- 2017
4.6 Subjects Recruited by Year, 2010- 2017
4.7 Clinical Trials by Development Phase, 2010- 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010- 2017
4.9 Clinical Trials by Status, 2010- 2017
4.10 Subjects Recruited by Trial Status, 2010- 2017
4.11 Clinical Trials by Sponsor Type, 2010- 2017
4.12 Subjects Recruited by Sponsor Type, 2010- 2017
4.13 Clinical Trials by Economy Type, 2010- 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010- 2017
5 EUROPE HYPERTHYROIDISM CLINICAL TRIAL RESEARCH TRENDS
5.1 Clinical Trials by Top Countries in Europe, 2010- 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010- 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010- 2017
5.4 Europe, Clinical Trials by Development Phase, 2010- 2017
5.5 Europe, Clinical Trials by Trial Status, 2010- 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010- 2017
6 WESTERN PACIFIC HYPERTHYROIDISM CLINICAL TRIAL RESEARCH TRENDS
6.1 Clinical Trials by Top Countries in Western Pacific, 2010- 2017
6.1.1 Western Pacific, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in Western Pacific, 2010- 2017
6.2.1 Western Pacific, Total Enrolment by Country
6.3 Western Pacific, Clinical Trials by Year, 2010- 2017
6.4 Western Pacific, Clinical Trials by Development Phase, 2010- 2017
6.5 Western Pacific, Clinical Trials by Trial Status, 2010- 2017
6.6 Western Pacific, Clinical Trials by Sponsor Type, 2010- 2017
7 REST OF WORLD HYPERTHYROIDISM CLINICAL TRIAL RESEARCH TRENDS
7.1 Clinical Trials by Top Countries in Rest of World, 2010- 2017
7.1.1 Rest of World, Clinical Trials by Country
7.2 Subjects Recruited by Top Countries in Rest of World, 2010- 2017
7.2.1 Rest of World, Total Enrolment by Country
7.3 Rest of World, Clinical Trials by Year, 2010- 2017
7.4 Rest of World, Clinical Trials by Development Phase, 2010- 2017
7.5 Rest of World, Clinical Trials by Trial Status, 2010- 2017
7.6 Rest of World, Clinical Trials by Sponsor Type, 2010- 2017
8 RECENT CLINICAL TRIALS- SNAPSHOTS
8.1 Hyperthyroidism Trial Snapshots- 2017
8.2 Hyperthyroidism Trial Snapshots- 2017
8.3 Hyperthyroidism Trial Snapshots- 2015
8.4 Hyperthyroidism Trial Snapshots- 2014
8.5 Hyperthyroidism Trial Snapshots- 2013
8.6 Hyperthyroidism Trial Snapshots- 2012
8.7 Hyperthyroidism Trial Snapshots- 2011
8.8 Hyperthyroidism Trial Snapshots- 2010
9 APPENDIX
9.1 About VPA Research
9.2 Sources and Research Methodology
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 Report Guide
2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010- 2017
2.2.3 Prominent Companies in Global Hyperthyroidism Trials, 2010- 2017
3 HYPERTHYROIDISM DRUGS IN ONGOING AND COMPLETED TRIALS
3.1 Prominent Drugs in Development and Approved Stages for Hyperthyroidism
3.2 Hyperthyroidism Product Snapshots
3.2.1 Hyperthyroidism Drug Profiles
4 GLOBAL HYPERTHYROIDISM CLINICAL TRIAL RESEARCH TRENDS
4.1 Clinical Trials by Top 10 Countries, 2010- 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010- 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010- 2017
4.4 Subjects Recruited by Region, 2010- 2017
4.5 Clinical Trials by Year, 2010- 2017
4.6 Subjects Recruited by Year, 2010- 2017
4.7 Clinical Trials by Development Phase, 2010- 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010- 2017
4.9 Clinical Trials by Status, 2010- 2017
4.10 Subjects Recruited by Trial Status, 2010- 2017
4.11 Clinical Trials by Sponsor Type, 2010- 2017
4.12 Subjects Recruited by Sponsor Type, 2010- 2017
4.13 Clinical Trials by Economy Type, 2010- 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010- 2017
5 EUROPE HYPERTHYROIDISM CLINICAL TRIAL RESEARCH TRENDS
5.1 Clinical Trials by Top Countries in Europe, 2010- 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010- 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010- 2017
5.4 Europe, Clinical Trials by Development Phase, 2010- 2017
5.5 Europe, Clinical Trials by Trial Status, 2010- 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010- 2017
6 WESTERN PACIFIC HYPERTHYROIDISM CLINICAL TRIAL RESEARCH TRENDS
6.1 Clinical Trials by Top Countries in Western Pacific, 2010- 2017
6.1.1 Western Pacific, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in Western Pacific, 2010- 2017
6.2.1 Western Pacific, Total Enrolment by Country
6.3 Western Pacific, Clinical Trials by Year, 2010- 2017
6.4 Western Pacific, Clinical Trials by Development Phase, 2010- 2017
6.5 Western Pacific, Clinical Trials by Trial Status, 2010- 2017
6.6 Western Pacific, Clinical Trials by Sponsor Type, 2010- 2017
7 REST OF WORLD HYPERTHYROIDISM CLINICAL TRIAL RESEARCH TRENDS
7.1 Clinical Trials by Top Countries in Rest of World, 2010- 2017
7.1.1 Rest of World, Clinical Trials by Country
7.2 Subjects Recruited by Top Countries in Rest of World, 2010- 2017
7.2.1 Rest of World, Total Enrolment by Country
7.3 Rest of World, Clinical Trials by Year, 2010- 2017
7.4 Rest of World, Clinical Trials by Development Phase, 2010- 2017
7.5 Rest of World, Clinical Trials by Trial Status, 2010- 2017
7.6 Rest of World, Clinical Trials by Sponsor Type, 2010- 2017
8 RECENT CLINICAL TRIALS- SNAPSHOTS
8.1 Hyperthyroidism Trial Snapshots- 2017
8.2 Hyperthyroidism Trial Snapshots- 2017
8.3 Hyperthyroidism Trial Snapshots- 2015
8.4 Hyperthyroidism Trial Snapshots- 2014
8.5 Hyperthyroidism Trial Snapshots- 2013
8.6 Hyperthyroidism Trial Snapshots- 2012
8.7 Hyperthyroidism Trial Snapshots- 2011
8.8 Hyperthyroidism Trial Snapshots- 2010
9 APPENDIX
9.1 About VPA Research
9.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Hyperthyroidism- Average Enrolment by Country, 2010- 2017
Figure 2: Hyperthyroidism- Country wise Clinical Trials, 2010- 2017
Figure 3: Hyperthyroidism- Country wise Recruiting Sites, 2010- 2017
Figure 4: Hyperthyroidism- Country wise Subjects Recruited, 2010- 2017
Figure 5: Global Hyperthyroidism Clinical Trials Participation Share by Region, 2010- 2017
Figure 6: Global Hyperthyroidism Subjects Recruited by Region, 2010- 2017
Figure 7: Global Hyperthyroidism Clinical Trials by Year, 2010- 2017
Figure 8: Global Hyperthyroidism Subjects Recruited by Year, 2010- 2017
Figure 9: Global Hyperthyroidism Trials by Phase, 2010- 2017
Figure 10: Global Hyperthyroidism- Subjects Recruited by Phase, 2010- 2017
Figure 11: Global Hyperthyroidism- Clinical Trials by Recruitment Status, 2010- 2017
Figure 12: Global Hyperthyroidism- Subjects Recruited by Trial Status, 2010- 2017
Figure 13: Global Hyperthyroidism- Clinical Trials by Sponsor Type, 2010- 2017
Figure 14: Global Hyperthyroidism- Subjects Recruited by Trial Status, 2010- 2017
Figure 15: Global Hyperthyroidism- Clinical Trials by Type of Economy, 2010- 2017
Figure 16: Europe Hyperthyroidism- Country wise Clinical Trials, 2010- 2017
Figure 17: Europe Hyperthyroidism- Country wise Subjects Recruited, 2010- 2017
Figure 18: Europe Hyperthyroidism- Year wise Clinical Trials, 2010- 2017
Figure 19: Europe Hyperthyroidism Trials by Phase, 2010- 2017
Figure 20: Europe Hyperthyroidism- Clinical Trials by Recruitment Status, 2010- 2017
Figure 21: Europe Hyperthyroidism- Clinical Trials by Sponsor Type, 2010- 2017
Figure 22: Western Pacific Hyperthyroidism- Country wise Clinical Trials, 2010- 2017
Figure 23: Western Pacific Hyperthyroidism- Country wise Subjects Recruited, 2010- 2017
Figure 24: Western Pacific Hyperthyroidism- Year wise Clinical Trials, 2010- 2017
Figure 25: Western Pacific Hyperthyroidism Trials by Phase, 2010- 2017
Figure 26: Western Pacific Hyperthyroidism- Clinical Trials by Recruitment Status, 2010- 2017
Figure 27: Western Pacific Hyperthyroidism- Clinical Trials by Sponsor Type, 2010- 2017
Figure 28: Rest of World Hyperthyroidism- Country wise Clinical Trials, 2010- 2017
Figure 29: Rest of World Hyperthyroidism- Country wise Subjects Recruited, 2010- 2017
Figure 30: Rest of World Hyperthyroidism- Year wise Clinical Trials, 2010- 2017
Figure 31: Rest of World Hyperthyroidism Trials by Phase, 2010- 2017
Figure 32: Rest of World Hyperthyroidism- Clinical Trials by Recruitment Status, 2010- 2017
Figure 33: Rest of World Hyperthyroidism- Clinical Trials by Sponsor Type, 2010- 2017
Figure 1: Hyperthyroidism- Average Enrolment by Country, 2010- 2017
Figure 2: Hyperthyroidism- Country wise Clinical Trials, 2010- 2017
Figure 3: Hyperthyroidism- Country wise Recruiting Sites, 2010- 2017
Figure 4: Hyperthyroidism- Country wise Subjects Recruited, 2010- 2017
Figure 5: Global Hyperthyroidism Clinical Trials Participation Share by Region, 2010- 2017
Figure 6: Global Hyperthyroidism Subjects Recruited by Region, 2010- 2017
Figure 7: Global Hyperthyroidism Clinical Trials by Year, 2010- 2017
Figure 8: Global Hyperthyroidism Subjects Recruited by Year, 2010- 2017
Figure 9: Global Hyperthyroidism Trials by Phase, 2010- 2017
Figure 10: Global Hyperthyroidism- Subjects Recruited by Phase, 2010- 2017
Figure 11: Global Hyperthyroidism- Clinical Trials by Recruitment Status, 2010- 2017
Figure 12: Global Hyperthyroidism- Subjects Recruited by Trial Status, 2010- 2017
Figure 13: Global Hyperthyroidism- Clinical Trials by Sponsor Type, 2010- 2017
Figure 14: Global Hyperthyroidism- Subjects Recruited by Trial Status, 2010- 2017
Figure 15: Global Hyperthyroidism- Clinical Trials by Type of Economy, 2010- 2017
Figure 16: Europe Hyperthyroidism- Country wise Clinical Trials, 2010- 2017
Figure 17: Europe Hyperthyroidism- Country wise Subjects Recruited, 2010- 2017
Figure 18: Europe Hyperthyroidism- Year wise Clinical Trials, 2010- 2017
Figure 19: Europe Hyperthyroidism Trials by Phase, 2010- 2017
Figure 20: Europe Hyperthyroidism- Clinical Trials by Recruitment Status, 2010- 2017
Figure 21: Europe Hyperthyroidism- Clinical Trials by Sponsor Type, 2010- 2017
Figure 22: Western Pacific Hyperthyroidism- Country wise Clinical Trials, 2010- 2017
Figure 23: Western Pacific Hyperthyroidism- Country wise Subjects Recruited, 2010- 2017
Figure 24: Western Pacific Hyperthyroidism- Year wise Clinical Trials, 2010- 2017
Figure 25: Western Pacific Hyperthyroidism Trials by Phase, 2010- 2017
Figure 26: Western Pacific Hyperthyroidism- Clinical Trials by Recruitment Status, 2010- 2017
Figure 27: Western Pacific Hyperthyroidism- Clinical Trials by Sponsor Type, 2010- 2017
Figure 28: Rest of World Hyperthyroidism- Country wise Clinical Trials, 2010- 2017
Figure 29: Rest of World Hyperthyroidism- Country wise Subjects Recruited, 2010- 2017
Figure 30: Rest of World Hyperthyroidism- Year wise Clinical Trials, 2010- 2017
Figure 31: Rest of World Hyperthyroidism Trials by Phase, 2010- 2017
Figure 32: Rest of World Hyperthyroidism- Clinical Trials by Recruitment Status, 2010- 2017
Figure 33: Rest of World Hyperthyroidism- Clinical Trials by Sponsor Type, 2010- 2017
LIST OF TABLES
Table 1: Hyperthyroidism Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (1)
Table 2: Hyperthyroidism Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (2)
Table 3: Hyperthyroidism- Region wise Clinical Trials, 2010- 2017
Table 4: Hyperthyroidism- Region wise Subjects Recruited, 2010- 2017
Table 5: Global Hyperthyroidism- Clinical Trials and Subjects by Trial Type, 2010- 2017
Table 6: Hyperthyroidism Trial Snapshots- 2017
Table 7: Hyperthyroidism Trial Snapshots- 2017
Table 8: Hyperthyroidism Trial Snapshots- 2017
Table 9: Hyperthyroidism Trial Snapshots- 2016
Table 10: Hyperthyroidism Trial Snapshots- 2016
Table 11: Hyperthyroidism Trial Snapshots- 2016
Table 12: Hyperthyroidism Trial Snapshots- 2016
Table 13: Hyperthyroidism Trial Snapshots- 2016
Table 14: Hyperthyroidism Trial Snapshots- 2016
Table 15: Hyperthyroidism Trial Snapshots- 2016
Table 16: Hyperthyroidism Trial Snapshots- 2016
Table 17: Hyperthyroidism Trial Snapshots- 2015
Table 18: Hyperthyroidism Trial Snapshots- 2015
Table 19: Hyperthyroidism Trial Snapshots- 2014
Table 20: Hyperthyroidism Trial Snapshots- 2014
Table 21: Hyperthyroidism Trial Snapshots- 2014
Table 22: Hyperthyroidism Trial Snapshots- 2014
Table 23: Hyperthyroidism Trial Snapshots- 2014
Table 24: Hyperthyroidism Trial Snapshots- 2013
Table 25: Hyperthyroidism Trial Snapshots- 2013
Table 26: Hyperthyroidism Trial Snapshots- 2012
Table 27: Hyperthyroidism Trial Snapshots- 2012
Table 28: Hyperthyroidism Trial Snapshots- 2012
Table 29: Hyperthyroidism Trial Snapshots- 2012
Table 30: Hyperthyroidism Trial Snapshots- 2012
Table 31: Hyperthyroidism Trial Snapshots- 2011
Table 32: Hyperthyroidism Trial Snapshots- 2010
Table 33: Hyperthyroidism Trial Snapshots- 2010
Table 1: Hyperthyroidism Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (1)
Table 2: Hyperthyroidism Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (2)
Table 3: Hyperthyroidism- Region wise Clinical Trials, 2010- 2017
Table 4: Hyperthyroidism- Region wise Subjects Recruited, 2010- 2017
Table 5: Global Hyperthyroidism- Clinical Trials and Subjects by Trial Type, 2010- 2017
Table 6: Hyperthyroidism Trial Snapshots- 2017
Table 7: Hyperthyroidism Trial Snapshots- 2017
Table 8: Hyperthyroidism Trial Snapshots- 2017
Table 9: Hyperthyroidism Trial Snapshots- 2016
Table 10: Hyperthyroidism Trial Snapshots- 2016
Table 11: Hyperthyroidism Trial Snapshots- 2016
Table 12: Hyperthyroidism Trial Snapshots- 2016
Table 13: Hyperthyroidism Trial Snapshots- 2016
Table 14: Hyperthyroidism Trial Snapshots- 2016
Table 15: Hyperthyroidism Trial Snapshots- 2016
Table 16: Hyperthyroidism Trial Snapshots- 2016
Table 17: Hyperthyroidism Trial Snapshots- 2015
Table 18: Hyperthyroidism Trial Snapshots- 2015
Table 19: Hyperthyroidism Trial Snapshots- 2014
Table 20: Hyperthyroidism Trial Snapshots- 2014
Table 21: Hyperthyroidism Trial Snapshots- 2014
Table 22: Hyperthyroidism Trial Snapshots- 2014
Table 23: Hyperthyroidism Trial Snapshots- 2014
Table 24: Hyperthyroidism Trial Snapshots- 2013
Table 25: Hyperthyroidism Trial Snapshots- 2013
Table 26: Hyperthyroidism Trial Snapshots- 2012
Table 27: Hyperthyroidism Trial Snapshots- 2012
Table 28: Hyperthyroidism Trial Snapshots- 2012
Table 29: Hyperthyroidism Trial Snapshots- 2012
Table 30: Hyperthyroidism Trial Snapshots- 2012
Table 31: Hyperthyroidism Trial Snapshots- 2011
Table 32: Hyperthyroidism Trial Snapshots- 2010
Table 33: Hyperthyroidism Trial Snapshots- 2010
